[go: up one dir, main page]

EP1581261A4 - Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90 - Google Patents

Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90

Info

Publication number
EP1581261A4
EP1581261A4 EP03741983A EP03741983A EP1581261A4 EP 1581261 A4 EP1581261 A4 EP 1581261A4 EP 03741983 A EP03741983 A EP 03741983A EP 03741983 A EP03741983 A EP 03741983A EP 1581261 A4 EP1581261 A4 EP 1581261A4
Authority
EP
European Patent Office
Prior art keywords
cytotoxins
diagnostic imaging
imaging agents
hsp90 ligands
hsp90
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03741983A
Other languages
German (de)
English (en)
Other versions
EP1581261A1 (fr
Inventor
Adeela Kamal
Francis Burrows
Lin Zhang
Marcus Boehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/039993 external-priority patent/WO2003050295A2/fr
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of EP1581261A1 publication Critical patent/EP1581261A1/fr
Publication of EP1581261A4 publication Critical patent/EP1581261A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03741983A 2002-12-12 2003-06-12 Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90 Withdrawn EP1581261A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2002/039993 WO2003050295A2 (fr) 2001-12-12 2002-12-12 Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90
WOPCT/US02/39993 2002-12-12
PCT/US2003/018776 WO2004054624A1 (fr) 2002-12-12 2003-06-12 Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90

Publications (2)

Publication Number Publication Date
EP1581261A1 EP1581261A1 (fr) 2005-10-05
EP1581261A4 true EP1581261A4 (fr) 2009-10-21

Family

ID=32592278

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03741983A Withdrawn EP1581261A4 (fr) 2002-12-12 2003-06-12 Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90

Country Status (4)

Country Link
EP (1) EP1581261A4 (fr)
AU (1) AU2003303058A1 (fr)
CA (1) CA2549463A1 (fr)
WO (1) WO2004054624A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (fr) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthèse d'épothilones, intermédiaires, analogues et leurs utilisations
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
GB0526615D0 (en) * 2005-12-30 2006-02-08 Novartis Ag Organic compounds
GB0603880D0 (en) * 2006-02-27 2006-04-05 Novartis Ag Organic compounds
CN100519536C (zh) * 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
KR20100074177A (ko) 2007-09-10 2010-07-01 유니버시티 오브 매사추세츠 미토콘드리아-표적화된 항-종양 물질
US20110270151A1 (en) * 2008-09-08 2011-11-03 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2015038649A1 (fr) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Thérapeutique ciblée
WO2015066053A2 (fr) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Thérapies ciblées
JP2017505777A (ja) 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
CA2941618A1 (fr) 2014-03-03 2015-09-11 Synta Pharmaceuticals Corp. Therapies ciblees
WO2015143004A1 (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp. Agents thérapeutiques cibles
IL299893A (en) 2017-06-20 2023-03-01 Madrigal Pharmaceuticals Inc prescribed medications
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003737A2 (fr) * 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Medicaments solubles a l'eau et procedes de preparation de ceux-ci
WO2003045319A2 (fr) * 2001-11-21 2003-06-05 Activbiotics, Inc. Agents therapeutiques cibles et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003737A2 (fr) * 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Medicaments solubles a l'eau et procedes de preparation de ceux-ci
WO2003045319A2 (fr) * 2001-11-21 2003-06-05 Activbiotics, Inc. Agents therapeutiques cibles et leurs utilisations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 224, no. 1-2, 2002, 224TH NATIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY; BOSTON, MA, USA; AUGUST 18-22, 2002, pages BIOT 64, ISSN: 0065-7727 *
CHIOSIS GABRIELA ET AL: "A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells", CHEMISTRY AND BIOLOGY, vol. 8, no. 3, March 2001 (2001-03-01), LONDON, pages 289 - 299, XP002542023, ISSN: 1074-5521 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, MANDLER RAYA ET AL: "Strategies in conjugating geldanamycin derivatives to monoclonal antibodies that enhance herceptin efficacy in mice bearing HER2-overexpressing xenografts", XP002542020, Database accession no. PREV200200490291 *
FUKAZAWA H ET AL: "Labeling of v-Src and BCR-ABL tyrosine kinases with [<14>C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism", FEBS LETTERS, vol. 340, no. 3, 1994, NL, pages 155 - 158, XP002542022, ISSN: 0014-5793 *
MANDLER R ET AL: "Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin TM immunoconjugate", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 10, 1 May 2000 (2000-05-01), PERGAMON, ELSEVIER SCIENCE, GB, pages 1025 - 1028, XP004204597, ISSN: 0960-894X *
SCHNUR R C ET AL: "Preparation of 17-amino-22-(4'-azido-3'-<125>iodophenacyl)-17- demethoxygeldanamycin (1): An ansamycin for photoaffinity labeling", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 34, no. 6, 1994, GB, pages 529 - 536, XP002542021, ISSN: 0362-4803 *
See also references of WO2004054624A1 *

Also Published As

Publication number Publication date
WO2004054624A1 (fr) 2004-07-01
CA2549463A1 (fr) 2004-07-01
AU2003303058A1 (en) 2004-07-09
EP1581261A1 (fr) 2005-10-05

Similar Documents

Publication Publication Date Title
EP1581261A4 (fr) Cytotoxines et agents d&#39;imagerie de diagnostic comprenant des ligands hsp90
GB0009179D0 (en) Non-invasive prenatal diagnosis
EP1372739A4 (fr) Agents therapeutiques et d&#39;imagerie stabilises
EP1637064A4 (fr) Endoscope gaine et systeme d&#39;endoscope gaine
EP1390393A4 (fr) Composes pentapeptidiques et leurs utilisations
AU2002327185A8 (en) Diagnostic methods and devices
AU2003277183A8 (en) Improved diagnostic fluorescence and reflectance
AU2003282810A8 (en) Integrated multi-rail imaging system
EP1572741A4 (fr) Agents diagnostiques et therapeutiques
AU2002346086A1 (en) Diagnostic imaging tabletop
GB0126298D0 (en) Fault diagnosis
GB2396909B (en) Glare-directed imaging
GB0209892D0 (en) Imaging assembly
IL153183A0 (en) Agents for imaging and diagnostic methods using them
IL132488A0 (en) Dopamine transporter imaging agents
AU2003245589A8 (en) System and method for noninvasive diagnostic imaging
GB9926805D0 (en) Diagnostic methods
PL1670762T3 (pl) Pirydyloacetyleny do zastosowania jako radioznaczniki i środki obrazujące
AU2003274588A8 (en) Diagnostic x-ray system
GB0120009D0 (en) Cause and effect diagnosis
EP1531852A4 (fr) Activation de caspase 9 et utilisations associees
IL150906A0 (en) Diagnostic microspheres
GB0201239D0 (en) Tissue imaging at superharmonic frequencies
AU2001247533A1 (en) Functional radiographic imaging methods and agents
IL150016A0 (en) Agents for imaging and diagnostic methods using them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOEHM, MARCUS

Inventor name: ZHANG, LIN

Inventor name: BURROWS, FRANCIS

Inventor name: KAMAL, ADEELA

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20090907BHEP

Ipc: A61M 36/14 20060101ALI20090907BHEP

Ipc: A61K 51/00 20060101AFI20040705BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091223